Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Joel C Scherer"'
Autor:
David Monteith, Emily C. Collins, Corinne Vandermeulen, Anne Van Hecken, Eyas Raddad, Joel C. Scherer, David Grayzel, Thomas J. Schuetz, Jan de Hoon
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2017)
Background: Calcitonin gene-related peptide (CGRP) is pivotal in the pathophysiology of migraine headaches and represents a promising target for migraine treatment. The humanized monoclonal antibody galcanezumab (LY2951742) binds to CGRP and may be e
Externí odkaz:
https://doaj.org/article/575cfbd32890489aa7734d36b48339e5
Autor:
Egilius L.H. Spierings, Joel C Scherer, Peter J. Goadsby, Steven Sweeney, David W. Dodick, David S Grayzel
Publikováno v:
The Lancet Neurology. 13:885-892
Summary Background Migraine remains poorly treated, with few effective preventive drugs available. We assessed the safety and efficacy of LY2951742, a fully humanised monoclonal antibody to calcitonin gene-related peptide, for migraine prevention. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a98635b472e650c3947a23274be825
https://doi.org/10.1016/s1474-4422(14)70128-0
https://doi.org/10.1016/s1474-4422(14)70128-0
Autor:
Andrea De Gaetano, William H. Landschulz, John Polzer, Jeffrey W. Miller, Eyas Abu-Raddad, Jolene K. Berg, Joel C Scherer, Joanne Sloan-Lancaster
Publikováno v:
Diabetes Care
OBJECTIVE Inflammation is associated with pancreatic β-cell apoptosis and reduced insulin sensitivity. Literature suggests that interleukin (IL)-1β may contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). This study aimed to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c504ec3a3cc9cee002a99ddccf2f4d1f
https://doi.org/10.2337/dc12-1835
https://doi.org/10.2337/dc12-1835
Autor:
John R. Stille, Paul K. Owens, Kenneth G. Olovich, Eyas Raddad, Neil Smith, Rosie S. Jones, Joel C Scherer, Jeffrey W. Miller
Publikováno v:
Nature reviews. Drug discovery. 14(1)
Chorus is a small, operationally independent organization within Eli Lilly and Company that specializes in drug development from candidate selection through to clinical proof of concept. Here, we describe its development philosophy, organizational st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83ffe132750b6f1d3785f218310de507
https://pubmed.ncbi.nlm.nih.gov/25503514
https://pubmed.ncbi.nlm.nih.gov/25503514
Autor:
Peter J. Goadsby, David S Grayzel, Egilius L.H. Spierings, David W. Dodick, Joel C Scherer, Steven Sweeney
Publikováno v:
The Lancet. Neurology. 14(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::964984d7ca0257f4e8935c3011a09486
https://pubmed.ncbi.nlm.nih.gov/25496894
https://pubmed.ncbi.nlm.nih.gov/25496894
Autor:
Howard A. Cooper, Keaven M. Anderson, J.A. de Lemos, Eugene Braunwald, F. Van de Werf, Sean P. Murphy, P Coussement, Carolyn H. McCabe, Joel C Scherer, Charles Michael Gibson, Elliott M. Antman, Robert P. Giugliano
Publikováno v:
European Heart Journal. 23:928-933
Background When evaluating new reperfusion regimens for ST elevation MI, it is important to adjust for factors that influence the likelihood of achieving normal epicardial flow and complete ST resolution. Methods and Results A total of 610 patients f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b412d3b6e3bc35bbe5c5563b9555a7d8
https://doi.org/10.1053/euhj.2001.2964
https://doi.org/10.1053/euhj.2001.2964
Publikováno v:
Catheterization and Cardiovascular Interventions. 53:296-303
The purpose of this study is to compare the profile of percutaneous coronary intervention (PCI) patients who receive abciximab versus eptifibatide, as well as to compare the effect of abciximab versus eptifibatide on hospital length of stay. Retrospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec4c152b7c49ef80fcbcbe2dd3ed46d
https://doi.org/10.1002/ccd.1170
https://doi.org/10.1002/ccd.1170
Autor:
Christoph A. Nienaber, D Andresen, Keaven M. Anderson, Joel C Scherer, P Coussement, Ian Menown, Martin J. Frey, C M Gibson, J.A. de Lemos, T.C Rehders, Carolyn H. McCabe, R. Van der Wieken, Eugene Braunwald, Elliott M. Antman, Robert P. Giugliano, F. Van de Werf
Publikováno v:
European Heart Journal. 21:1944-1953
Aims Abciximab has previously been shown to enhance thrombolysis and improve myocardial perfusion when combined with reduced doses of alteplase. The purpose of the reteplase phase of TIMI 14 was to evaluate the effects of abciximab when used in combi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7eb45a25f4d7d8afb185418c8d3fb426
https://doi.org/10.1053/euhj.2000.2243
https://doi.org/10.1053/euhj.2000.2243
Autor:
Neal S. Kleiman, Joel C Scherer, Eugene Braunwald, Elliott M. Antman, Christopher P. Cannon, Stephanie Coulter, Kenneth A. Ault, Elliot S. Barnathan, Robert P. Giugliano, A.A.Jennifer Adgey, Frans Van de Werf, Mary Ann Mascelli, C. Michael Gibson
Publikováno v:
Circulation. 101:2690-2695
Background —We evaluated platelet activation and aggregation in patients with acute myocardial infarction (AMI) treated with thrombolytic therapy alone or with reduced-dose thrombolysis and concomitant abciximab. Methods and Results —The study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8113d19d924b3da93c7077146cc0a77
https://doi.org/10.1161/01.cir.101.23.2690
https://doi.org/10.1161/01.cir.101.23.2690
Autor:
Frans Van de Werf, Eugene Braunwald, Sabina A. Murphy, Martin J. Frey, James A. de Lemos, Carolyn H. McCabe, C. Michael Gibson, Robert P. Giugliano, Stephanie Coulter, Keaven M. Anderson, R. Van der Wieken, Elliott M. Antman, Joel C Scherer
Publikováno v:
Circulation. 101:239-243
Background —In the presence of ST-elevation myocardial infarction, patients with successful epicardial reperfusion (TIMI 3 flow) but persistent ST elevation on a 12-lead ECG are at high risk for subsequent death and left ventricular dysfunction. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc783cb52ff34e4c60f92c9634b411d1
https://doi.org/10.1161/01.cir.101.3.239
https://doi.org/10.1161/01.cir.101.3.239